Join us for an informative session on funding strategies for early-stage clinical trials. This Masterclass will explore the key considerations when choosing between public and private funding options, including the implications of listing early on the ASX. Whether you're preparing to start your first trial or seeking to understand the longer-term funding landscape, this session will provide practical insights to support your decision-making.

Key areas we'll explore include:

Why starting clinical trials is a decision point for public v private funding?
What are the considerations in choosing private funding or listing to finance early stage clinical trials?
Does early listing on the ASX limit options for later stage product development?
When considering listing, how to weigh up cost and compliance with access to funding?

Brief agenda:

2:30pm Registration and passing through security

3:00pm: Masterclass begins

4:00pm: Networking and refreshments

Meet your Speakers:

Matt McNamara, Chief Investment Officer & Board Director at Horizon 3 Healthcare
Matt McNamara is passionate about commercialising promising human healthcare technologies. His business acumen combined with a strong background in the life sciences sector makes him one of the industry’s most credible investment voices. Currently, Matt continues to invest in and commercialise great healthcare technologies through an exciting portfolio of executive/non-executive board and advisory roles. Previously, Matt spent over 30 years in the healthcare and medical sciences sector, with more than 20 years as a venture capitalist. He spent fourteen years as CIO at BioScience Managers (4 funds. $200M FUM. >20% IRR), and was previously CEO of SciCapital pre-seed fund. Prior to that he served as SVP Business Development for eBioinformatics Inc. Early in his career, Matt spent over a decade in the Pharma industry working in sales and marketing with Merck & Co. and in general management at Johnson and Johnson Medical Pty Ltd. Matt has a BSc (Hons) in Molecular Biology, an MBA, and is a GAICD.

NOTE: You may be photographed or videod while attending this event for marketing purposes: please approach the organiser if you have questions, concerns, or do not wish this to happen.

The masterclass will be followed by an optional tour of Jumar Bioincubator. Let us know in the registration form if you're interested in participating.

About

Jumar Bioincubator acts as a first home for biotech startups, providing affordable lab and office space, practical support, and community activities to unlock the potential in early scientific discoveries.

Jumar Bioincubator was established by CSL, WEHI and the University of Melbourne. Together, with backing from innovation investor Breakthrough Victoria and operator Cicada Innovations, the mission is to connect early-stage and scaling biotech ventures with the support they need to progress discoveries towards real-world treatments and therapies and build a critical mass of scientists with the knowledge and confidence to run successful biomedical ventures.